This phase 1b/2 trial is evaluating the safety and effectiveness of using the current standard of care (chemotherapy [FOLFOX] and target therapies [bevacizumab]) in combination with novel targeted therapies (durvalumab and oleclumab) to treat metastatic microsatellite-stable colorectal cancer..
This trial is treating patients with Metastatic Microsatellite-stable Colorectal Cancer.
This is a systemic treatment.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b/2, Open-label, Multicenter Study of Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer
This study consists of two stages. Stage 1 is a phase 1b trial and will assess the safety of the new treatment regime. Stage 2 is a phase 2 trial which will be assessing the treatment safety and effectiveness. Patients eligible to participate in this study will receive either FOLFOX and bevacuzimab or FOLFOX, bevacuzimab, durvalumab and oleclumab. All treaments will be intravenously administered on Day 1 and 2 of a 14-week cycle.
Recruiting Hospitals Read More